This paper provides a detailed description of the microarray data as well as an indication of their value for evaluating cell signaling pathways (e.g. NFκB network) during the in vitro evaluation of anti-NASH compounds. The gene discussed is NFKB1; the disease is metabolic dysfunction-associated steatohepatitis.